menu

NEWS

Hummingbird Diagnostics to Present Poster on miLung Small RNA-Based Blood Test at the ASCO 2023 Annual Meeting

June 23, 2022 08:00 AM Eastern Daylight Time HEIDELBERG, Germany–(BUSINESS WIRE)–Hummingbird Diagnostics GmbH, a leader in reading blood-based small RNAs for early disease detection and characterization, today announced a poster presentation at the American Society for Clinical Oncology (ASCO) 2023 Annual Meeting on the miLung small RNA blood test for early-stage lung cancer detection. Details of the poster presentation are as follows: Title: Early detection of lung cancer using small RNAs Presenting Author: Bruno Steinkraus, PhD, Chief Scientific Officer of Hummingbird Diagnostics Session Title: Developmental Therapeutics – Molecularly Targeted Agents and Tumor Biology Abstract: #3035 Poster Board: #233 Location: Hall A Date/Time: June 3, 2023 from 8:00...

READ MORE
Clexio and Genetika+ announce partnership using proprietary antidepressant screening platform

Feb 06, 2023, 08:11 ET TEL AVIV and PETAH TIKVA, Israel, Feb. 6, 2023 /PRNewswire/ — As part of a shared commitment to bring better solutions for people suffering from depression, Clexio and Genetika+ are partnering to screen and characterize Clexio’s antidepressant pipeline using Genetika+’s iPSC-derived neurons platform. Genetika+’s platform encompasses >200 neuronal lines from depression patients with in-depth clinical and demographic characterization and multiple assessments over the course of 12 months, as well as proprietary multi-modal biomarker read-outs on these neurons. The Genetika+ platform allows, for the first time, assessment of the functional effects of drugs directly on human neurons, the key target cells...

READ MORE
Wastewater Testing Labs Can Automate Sample Processing for High Throughput With All-In-One Kit

New purification system launched by Promega includes Ceres Nanosciences’ Nanotrap® particles for virus concentration MADISON, Wis.–(BUSINESS WIRE)–Wastewater testing labs can now scale up their infectious disease surveillance using two reliable technologies in a single kit. The new system released by Promega Corporation pairs the company’s Maxwell® HT chemistry with Ceres Nanosciences’ Nanotrap® particles, an established technology for capturing and concentrating low-abundance analytes such as viral particles. Together, these technologies empower labs to purify pathogen nucleic acids from wastewater samples in high-throughput workflows. “Ceres has a technology that enables concentration of microbes from wastewater that is unique to the market”Tweet this “Ceres has a...

READ MORE
Ceres Nanosciences Receives $1.4M From NIH RADx Initiative to Add Five Additional Wastewater-Based Epidemiology Centers of Excellence

Manassas, Virginia – December 2, 2022 Ceres Nanosciences (Ceres), a privately held company that makes innovative products to improve life science research and diagnostic testing, is announcing today that it is expanding the network of wastewater-based epidemiology centers of excellence that was established with support from the National Institutes of Health (NIH) RADx® initiative. With a new $1.4 million award from the NIH, Ceres will identify and establish five additional centers of excellence to join the existing network of 16 sites comprising public health labs, non-profit labs, university labs, and commercial testing labs in 14 states. Ceres also will support the verification of...

READ MORE
Genetika+ Snags CE Mark for Major Depressive Disorder Drug-Matching Test

October 19, 2022 | Staff Reporter – genomeweb NEW YORK – Genetika+ has obtained CE-IVD marking for its first drug-matching test focused on major depressive disorder (MDD), the precision medicine startup said Wednesday. The Israeli company’s product, a blood test dubbed NeuroKaire, is ordered by a physician. It predicts a patient’s likelihood of responding to various antidepressants by combining patient-reported information about symptoms with pharmacogenetics testing and functional testing based on the patient’s blood sample.  The company’s CE mark follows results from a multi-site study, in which NeuroKaire successfully predicted drug response for patients with MDD. “This CE-IVD mark is an...

READ MORE
Genetika+ Combines PGx, ‘Brain-in-a-Dish’ Model to Personalize Depression Meds

October 11, 2022 | Jessica Kim Cohen – genomeweb NEW YORK – Genetika+ is combining information on patients’ symptoms, pharmacogenetics, and aso-called “brain-in-a-dish” functional testing model in the hopes of improving personalized drugprescribing for psychiatric conditions, with an initial focus on depression.  The Israeli company plans to launch its first drug-matching testing service for major depressivedisorder, dubbed NeuroKaire, next year. Genetika+ hopes to promote NeuroKaire as a service doctorscan use to improve patients’ outcomes on antidepressants, reduce treatment-related side effects, andcut down on trial-and-error prescribing. Millions of people across the globe struggle with major depressive disorder, and prevalence hasincreased with...

READ MORE
1 2 3 4 5 10
GreyBird Ventures

is named after the arctic tern, a bird that migrates 71,000 km annually. As they can live for 30 years, this is the lifetime equivalent of three trips to the moon and back. Not bad for a 100 gram bird. We strive to emulate its size to performance ratio as well as its global reach.

MEET THE PEOPLE

For additional information, please contact: greybird@greybirdventures.com

DISCLAIMER